Champions Oncology, Inc. filings document the reporting framework for a Nasdaq-listed oncology research services company with common stock registered under the Exchange Act. Recent 8-K reports cover results of operations and financial condition, press release exhibits, board and officer appointments, director resignations, and annual meeting voting results.
The company’s proxy materials disclose board elections, audit-firm ratification, executive and director compensation, equity awards, and other security-holder matters. Together, these filings record governance, compensation, capital-stock registration, and operating-result disclosures tied to the company’s translational oncology research services and data platform activities.
Champions Oncology, Inc. (CSBR) director Joel Ackerman exercised options covering 69,794 shares of common stock on October 15, 2026, at an exercise price of $1.60 per share. The transaction reported acquisition of 69,794 common shares, bringing his directly held common-stock position to 1,126,333 shares; the option position was reported as 0 following the exercise.
Champions Oncology, Inc. (CSBR) reported the results of its October 14, 2026 annual meeting. Stockholders elected all seven director nominees—Robert Brainin, Ronnie Morris, M.D., Joel Ackerman, David Sidransky, M.D., Daniel Mendelson, Scott R. Tobin and Brian Alexander, M.D.—to one-year terms expiring at the 2027 Annual Meeting of Stockholders. They ratified EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2027, approved the non-binding executive-compensation resolution and the 2026 Equity Incentive Plan, and recommended annual advisory votes on executive compensation. The company intends to hold those votes every year.
Champions Oncology, Inc. (CSBR) reported higher revenue but continued modest losses for the quarter ended July 31, 2026. Oncology revenue rose to $15.2 million from $14.0 million a year earlier, an 8.8% increase, driven mainly by pharmacology services and strong growth in data license revenue.
Net loss was $426,000 (basic loss per share $0.03), slightly improved from a $466,000 loss in the prior-year quarter as gross margin expanded; cost of oncology revenue fell 5.8% to $7.5 million. Operating cash flow was a use of $492,000 versus $600,000 provided a year ago, reflecting working-capital movements and higher operating spending.
Cash stood at $4.4 million with working capital of $563,000. Management states that existing cash and expected operating cash flows are adequate to fund operations through at least September 2027. Total assets increased to $33.3 million, mainly due to a long-term Rockville facility lease amendment that lifted operating right-of-use assets and lease liabilities. Internal controls over financial reporting are described as effective, and no material legal proceedings are disclosed.
Champions Oncology, Inc. (CSBR) reported first-quarter fiscal 2027 oncology revenue of $15.2 million, up 8.8% from $14.0 million a year earlier, driven by higher core research services and increased data license revenue. Oncology services margin improved to 51% from 43%, reflecting higher revenue and lower third-party radiolabeling costs.
The company recorded a net loss of $426,000, slightly better than the $466,000 loss in the prior-year period, and generated Adjusted EBITDA of $671,000, up from $59,000, as higher gross profit offset increased investment in R&D and commercial expansion. Operating expenses rose 7.7% to $15.6 million, including higher sales and marketing and stock-based compensation.
Net cash used in operating activities was $492,000 versus $600,000 provided in the prior-year quarter. Champions ended the quarter with $4.4 million in cash and no debt, total assets of $33.3 million, and deferred revenue of $9.6 million, indicating a solid backlog of contracted work despite ongoing net losses.
Champions Oncology, Inc. (CSBR) is soliciting proxies for its October 14, 2026 annual stockholder meeting at its Hackensack, New Jersey headquarters. Stockholders of record as of August 21, 2026, when 13,918,571 common shares were outstanding, are entitled to vote.
Stockholders are asked to elect seven directors, ratify EisnerAmper LLP as independent registered public accounting firm for the year ending April 30, 2027, approve a non-binding advisory vote on executive compensation, and vote on the frequency of future say‑on‑pay votes. They are also asked to approve a new 2026 Equity Incentive Plan, which would authorize equity awards for employees, directors, and consultants and is required for Nasdaq compliance and to grant incentive stock options.
The proxy describes a largely independent board (five of seven directors), committee structures, director pay, and detailed executive compensation, including a $3.57 million 2026 total package for CEO Robert Brainin and $388,464 for CFO David Miller. A pay‑versus‑performance table shows 2026 net loss of $1.175 million and adoption of a clawback policy effective December 1, 2023.
Champions Oncology, Inc. reported oncology revenue of $59.4 million for the year ended April 30 2026, up 4.4% from 2025, driven mainly by stronger pharmacology services. A sharp decline in large data-license deals and lower flow cytometry revenue reduced other TOS contributions.
Total costs and operating expenses rose 15.6% to $60.6 million, reflecting expanded R&D, sales, and G&A investments. Income from operations swung to a $1.1 million loss from $4.6 million profit, and net loss was approximately $1.2 million.
Operations used $4.5 million of cash versus $7.4 million provided in 2025. Cash was $4.9 million with negative working capital of $703,000 as of April 30 2026, and the company believes existing cash and expected operating cash flows can fund operations through at least August 2027.
Champions Oncology reported record fiscal 2026 oncology revenue of $59.4 million, up 4% from $56.9 million, driven by its core research services business despite the absence of approximately $4.5 million of prior-year data license revenue. Fourth-quarter revenue rose 12% to $13.8 million, and oncology services margin improved to 51% from 41% as costs of oncology revenue fell 6%.
Profitability weakened for the year. Champions posted a loss from operations of $1.1 million, versus income from operations of $4.6 million in fiscal 2025, and a GAAP net loss of $1.2 million versus prior-year net income of $4.7 million, reflecting higher outsourced radiopharmaceutical costs and increased R&D, sales and marketing, and G&A expenses. Adjusted EBITDA remained positive at $1.6 million, but declined from $7.1 million; in the fourth quarter, Adjusted EBITDA was $158,000 compared with a $1.2 million loss a year earlier.
Operating cash use in the fourth quarter was approximately $2.2 million, mainly from working-capital timing and lower deferred revenue. Champions ended April 30, 2026 with $4.9 million in cash and no debt while continuing to invest in radiopharmaceuticals, its data platform, and commercial organization.
Champions Oncology, Inc. reported that its Board of Directors accepted the resignation of Dr. Philip Breitfeld and appointed Dr. Brian Alexander as a director to fill the vacancy. The company stated that Dr. Breitfeld’s resignation was not due to any disagreement over operations, policies, or practices.
The company noted there is no arrangement or understanding with other persons regarding Dr. Alexander’s appointment, no related-party transactions requiring disclosure, and no material plans or contracts tied to his appointment. Dr. Alexander is an experienced oncology and data-science leader, currently serving as CEO of Valo Health and CEO-Partner at Flagship Pioneering.
Champions Oncology highlighted that his background in oncology, artificial intelligence, and data-driven drug development supports its strategy of linking patient-derived tumor models with molecular and clinical datasets to power a more data-informed translational research platform.
Champions Oncology reported slightly lower quarterly oncology revenue of $16.6M, down from $17.0M a year ago, and swung to a net loss of $0.3M compared with prior net income of $4.5M. Higher outsourced lab work, especially radiolabeling, plus increased research, sales, and administrative spending drove costs up faster than revenue.
For the nine months ended January 31, 2026, revenue rose modestly to $45.6M from $44.6M, but results moved from net income of $6.5M to a net loss of $0.5M. The company used $2.5M of cash in operations and ended the period with $7.1M in cash, negative working capital of about $0.5M, and an accumulated deficit of roughly $80.4M. Management nevertheless believes existing cash and expected operating cash flows can fund operations through at least March 2027.
Champions Oncology reported third quarter fiscal 2026 oncology revenue of $16.6 million, slightly below the prior year’s $17.0 million as a large $4.5 million data license from last year did not repeat. Study service revenue still grew about 32%, reflecting strong project execution.
The company posted a GAAP net loss of $279,000 versus net income of $4.5 million a year earlier, while adjusted EBITDA fell to $574,000 from $5.1 million as oncology services margin declined to 47% from 61% due to higher outsourced lab costs and mix shift.
For the nine months ended January 31, 2026, revenue edged up to $45.6 million from $44.6 million, but results swung to a net loss of $508,000 from $6.5 million of net income, with adjusted EBITDA decreasing to $1.5 million from $8.3 million. Champions ended the quarter with $7.1 million in cash and no debt, while increasing investment in R&D, sales and marketing, and its data platform to support future growth.